The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

With competition heating up, Pfizer may drop psoriasis effort on Xeljanz

Earlier this month, the FDA slapped down Pfizer's Xeljanz as a treatment for moderate to severe cases of plaque psoriasis. And that could be the end of the line for the med in that indication, execs said Tuesday.

Pfizer continues vaccines hot streak with 43% Q3 growth

After a strong first half, Pfizer's vaccine unit didn't let up in the third quarter, continuing on an upward trajectory as growing Prevnar 13 sales continued to propel the unit forward.

Pfizer juggles 'buckets of cash' abroad and at home in M&A review

On the company's third-quarter earnings call, Pfizer Chairman and CEO Ian Read fended off repeated questions on a new structure for the company that could be spurred by tax changes while letting a key executive paint a broad picture of how cash stashed abroad may play a part in any decision.

Pfizer blows past sales forecasts, thanks to overachievers Prevnar, Ibrance

Last quarter, vaccine giant Prevnar 13 and breast-cancer newcomer Ibrance outperformed expectations, helping Pfizer trump analyst estimates. And in Q3, they delivered repeat performances.

Pfizer cuts some biosimilar ties with Celltrion after its $17B Hospira deal

Pfizer, deepening its efforts in biosimilars after trading $17 billion for Hospira, is ditching a few redundant assets partnered with South Korean drugmaker Celltrion, paring down its pipeline as it eyes a growing global market.

Picture this: Pfizer advances its metastatic breast cancer awareness campaign with day-in-the-life photography

Pfizer is enlisting the power of pictures for its next chapter in its metastatic breast cancer awareness campaign. For "Story Half Told," the pharma has hired 5 prominent Instagram photographers to chronicle the everyday lives of women living with MBC.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.

Pfizer responds to FiercePharma

Tracy Staton wrote an article on Thursday, based on a piece in Forbes. Pfizer took exception to our article and sent a statement.

FDA swats down Pfizer's Xeljanz in plaque psoriasis

Pfizer will have to keep waiting on its hopes for Xeljanz (tofacitinib) expansion. For now, the FDA has turned down the slow-starting med as a treatment for moderate to severe cases of plaque psoriasis.

Pfizer CEO: Drug-pricing snafu isn't pharma's fault. It's insurers and their poor coverage

Pfizer CEO Ian Read says he's met the drug-cost enemy, and it isn't pharma. The firestorm over U.S. drug pricing isn't a problem for drugmakers to solve, Read told Forbes in an interview. It's an insurance problem.